Market Cap 468.13B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.09
Forward PE 18.62
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 1,404,267
Avg Vol 6,982,800
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 89%
Beta 0.30
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
DidYouReadThis
DidYouReadThis Aug. 25 at 7:09 PM
Do you think $OTLK #buyers or #sellers are more likely to know which drug in the wet AMD space has had the greatest number of total patients over the last 20 years? #Congrats to #Outlook #Therapeutics on #FDA #Approval! $REGN $ABBV $NVS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:46 PM
$SLS Gps is worth At LEAST $10B $49.50 per SLS Share Just for Ovarian Cancer Remission Maintenance ala $MRNA adding $40B for Melanoma Remission Maintenance. Gps has proven successful in ALL prior Trials, including 2 for AML Remission Maintenance as well as this Gps Phase 1/2 Combination Results w $MRK Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:28 PM
$SLS $ABBV We are at the finish Line. • 106 Days Since the 78th Event -- while we await 80 -- in a trial where we are AGAIN - like in ALL Prior GPS Trials - Seeing Truly Miraculous survival - for 49 CR2 - Second Remission Patients, who continue to Survive at Least 30 months, too frail, for Transplant, only a 8 month LE. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - again the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:18 PM
$SLS Of course, Gps Phase 1/2 Combination Results w Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---
2 · Reply
NotHopeJustFacts
NotHopeJustFacts Aug. 25 at 6:09 PM
$QTTB keep crying cause this molecule doesn't even match an already approved Rinvoq, why invest on an inferior product ? buy instead $ABBV if you care so much about Bold people, obviously is a stock for grown ups not a penny one
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 25 at 5:43 PM
$ABBV YTD 12/31/26 predictions to be closest to?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 5:36 PM
$SLS $ABBV $MRNA Is any day now a long time to wait for a 10 to 20 Bagger? We are at the finish Line. 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission Patients, who are too frail, for transplant. 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
1 · Reply
LT_Smash
LT_Smash Aug. 25 at 5:29 PM
$ABBV It is not a lot but I bought 25 shares in the last 2 month. I think this will pay out.
0 · Reply
Rogetrader
Rogetrader Aug. 25 at 3:53 PM
$ABBV Future Cash Flow Model has us valued at 440 in 18 months
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 1:53 PM
$SLS $ABBV the below is $40B getting added to the $MRNA market cap… based in P3 trial results - in a smaller market than Gps’s. Something very similar is about to happen here. Any Day Now.
0 · Reply
Latest News on ABBV
AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 8 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo


AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 15 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI


AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 20 days ago

AbbVie upgraded to Buy from Hold at Erste Group


AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 21 days ago

AbbVie price target raised to $288 from $261 at Guggenheim


AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 22 days ago

AbbVie price target raised to $290 from $282 at Canaccord


AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 25 days ago

AbbVie says ‘quite pleased’ with Skyrizi momentum


AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 25 days ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84


AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 25 days ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 25 days ago

AbbVie Earnings release: Q2 2026


AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 25 days ago

AbbVie Quarterly report: Q2 2026


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 25 days ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 26 days ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend


DidYouReadThis
DidYouReadThis Aug. 25 at 7:09 PM
Do you think $OTLK #buyers or #sellers are more likely to know which drug in the wet AMD space has had the greatest number of total patients over the last 20 years? #Congrats to #Outlook #Therapeutics on #FDA #Approval! $REGN $ABBV $NVS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:46 PM
$SLS Gps is worth At LEAST $10B $49.50 per SLS Share Just for Ovarian Cancer Remission Maintenance ala $MRNA adding $40B for Melanoma Remission Maintenance. Gps has proven successful in ALL prior Trials, including 2 for AML Remission Maintenance as well as this Gps Phase 1/2 Combination Results w $MRK Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:28 PM
$SLS $ABBV We are at the finish Line. • 106 Days Since the 78th Event -- while we await 80 -- in a trial where we are AGAIN - like in ALL Prior GPS Trials - Seeing Truly Miraculous survival - for 49 CR2 - Second Remission Patients, who continue to Survive at Least 30 months, too frail, for Transplant, only a 8 month LE. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - again the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:18 PM
$SLS Of course, Gps Phase 1/2 Combination Results w Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---
2 · Reply
NotHopeJustFacts
NotHopeJustFacts Aug. 25 at 6:09 PM
$QTTB keep crying cause this molecule doesn't even match an already approved Rinvoq, why invest on an inferior product ? buy instead $ABBV if you care so much about Bold people, obviously is a stock for grown ups not a penny one
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 25 at 5:43 PM
$ABBV YTD 12/31/26 predictions to be closest to?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 5:36 PM
$SLS $ABBV $MRNA Is any day now a long time to wait for a 10 to 20 Bagger? We are at the finish Line. 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission Patients, who are too frail, for transplant. 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
1 · Reply
LT_Smash
LT_Smash Aug. 25 at 5:29 PM
$ABBV It is not a lot but I bought 25 shares in the last 2 month. I think this will pay out.
0 · Reply
Rogetrader
Rogetrader Aug. 25 at 3:53 PM
$ABBV Future Cash Flow Model has us valued at 440 in 18 months
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 1:53 PM
$SLS $ABBV the below is $40B getting added to the $MRNA market cap… based in P3 trial results - in a smaller market than Gps’s. Something very similar is about to happen here. Any Day Now.
0 · Reply
GettnFibbywIT
GettnFibbywIT Aug. 25 at 1:15 PM
$ABBV $IHE $XLV ABBV continues to exhibit constructive post-breakout behavior following its successful reclaim and acceptance above the $236 resistance level. The subsequent consolidation and rounding pattern served to retest support without materially damaging the bullish structure, while momentum remained firmly in a bullish regime. More recently, price has achieved acceptance above the $260-$261 resistance area, suggesting buyers have absorbed another layer of overhead supply. Taken together, the evidence supports an ongoing bullish intermediate-term trend characterized by successful breakout retention, improving support structure, and momentum confirmation.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 12:16 PM
$SLS Gps has proven effective preventing relapse and extending survival in all 7 prior Trials - Including 2 Phase 2 Trials for AML remission maintenance ... and while we are seeing Miraculous Survival in this Imminently Finished P3 -- Aza+VEN the BAT for Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - including Failing 2 P3's for AML Maintenance - VIALE-M and VIALE-T FAILED. And yes despite yesterday’s higher than average 67% Short on LOW VOLUME in a DOWN Market -AFTER SLS CLOSED AT ITS HIGHEST PRICE IN 6 Years --- FINTEL CONFIRMS SHORTS are ATTEMPTING TO COVER ... - 10 15x Bagger ANY DAY NOW
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 5:41 AM
$SLS Gps has proven effective preventing relapse and extending survival in all 7 prior Trials - Including 2 Phase 2 Trials for AML remission maintenance ... and while we are seeing Miraculous Survival in this Imminently Finished P3 -- Aza+VEN the BAT for Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - including Failing 2 P3's for AML Maintenance - VIALE-M and VIALE-T FAILED. And yes despite today's 67% Short on LOW VOLUME in a DOWN Market -AFTER SLS CLOSED AT ITS HIGHEST PRICE IN 6 Years --- FINTEL CONFIRMS SHORTS are ATTEMPTING TO COVER ... 10 15x ANY DAY NOW
0 · Reply
itsallaboutheoptions
itsallaboutheoptions Aug. 25 at 5:33 AM
$ABBV 5,000 call contracts at 300 into December — 30% OTM, $614M exposure. Someone making a massive long-dated bet on AbbVie clearing $300 by year-end. 7-Day Free Trial! Get in now for SMS alerts, market data, and full chat access → https://itsallaboutheoptions.com/signup | Also available on iOS and Android
1 · Reply
TalkMarkets
TalkMarkets Aug. 25 at 12:25 AM
Sector Watch: Now #Biotech And #Healthcare Has The Momentum As Rotation Continues $ABT $ABBV $XBI $XLV $XLK https://talkmarkets.com/article/sector-watch-now-biotech-and-healthcare-has-the-momentum-as-rotation-continues-1787617441
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 24 at 5:07 PM
$RGNX $OTLK Who might have a higher market cap than the other by September 1, 2027? $ABBV $JNJ
0 · Reply
HawkEye828
HawkEye828 Aug. 24 at 1:06 PM
$PROK Nice Accumulation going on with this stock. Buy and Hold. Here is More educational info on Prok. This is a big deal! Government savings would be huge. National Kidney Foundation indicates Medicare actually spends $130 Bilion--moe then 24% of total spending on kidney disease. https://www.kidney.org/take-action/advocate/legislative-priorities/federal-investment J.P. Morgan conference--Phase 2 complete. 78% response rate with kidney stabilization. This is an Autologous treatment, using the patients own kidney cells. Alligned with FDA for Accelerated approval. Phase 3 on board. https://investors.prokidney.com/static-files/9159cbbe-5e36-468c-9c58-f3b3cc4fc428 $MRNA, $RHHBY, $LLY, $ABBV
0 · Reply
harmongreg
harmongreg Aug. 24 at 12:37 PM
4 Trade Ideas for AbbVie: Bonus Idea $ABBV https://dragonflycap.com/4-trade-ideas-for-abbvie-bonus-idea-8/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 24 at 6:06 AM
$SLS Onureg / Oral Az is the (BAT) Best Available Treatment for AML Patients in First Remission, who are ineligible for Transplant - MOS 24.7 months. GPs Phase 2 MOS was not reached and was GREATER THAN > 67.6 months in the same Exact First Remission Transplant Ineligible Setting. GPs MOS > 67.6 months / Control arm BAT Onureg 24.7 It is not complicated / OCCAMS Razor $ABBV conducted 3 Phase 3 trials combining Onureg with Venetoclax ... Aza+VEN - 3 Phase 3 Trials that FAILED - including the VIALE-M Ph3 Trial for Patients in First Remission Ineligible for Transplant - VIALE-M Failed Aza+VEN (BAT for the SLS P3 Control Arm FAILED ) - VIALE-T Failed -VERONA Failed OPTiAML FAILED
0 · Reply
Gramma
Gramma Aug. 24 at 4:42 AM
0 · Reply
StockConsultant
StockConsultant Aug. 24 at 3:11 AM
$ABBV Abbvie stock, watch for a top of range breakout at https://www.stockconsultant.com/?ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 23 at 2:24 AM
$SLS $MRNA $MRK pardon the typo -- .636 HR per the SAP -- and GPs gets the Fda green light. .636 Equates to a GPS MOS of 12.6 months vs ~8 with BAT for Control GPS Phase 3 Results are coming in close to 34/36 Months / w BAT in at ~ 8/10 ... Modern BAT / Aza+VEN recently Failed 3 Large Phase 3 Trials Conducted by $ABBV - including 2 for For AML Remission Maintenance. VIALE-M First Remissioin Maintenance p3 - failed VIALE-T Post Transplant Maintenance - Failed Gps has proven effective in Preventing Relapse and Extending Survival in all prior trials - with extended os correlated with WT1+ Specific Immune Response - including in 2 Phase 2 Trials for AML Remission Maintenance. it is not complicated.
0 · Reply